Liberty Wealth Management LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 7,461.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,493 shares of the company’s stock after purchasing an additional 11,341 shares during the quarter. Liberty Wealth Management LLC’s holdings in AstraZeneca were worth $192,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in AZN. Corsicana & Co. acquired a new position in shares of AstraZeneca during the 2nd quarter worth $30,000. Clearstead Advisors LLC grew its stake in AstraZeneca by 960.0% in the 2nd quarter. Clearstead Advisors LLC now owns 530 shares of the company’s stock valued at $32,000 after buying an additional 480 shares during the last quarter. Ten Capital Wealth Advisors LLC grew its stake in AstraZeneca by 112.8% in the 2nd quarter. Ten Capital Wealth Advisors LLC now owns 566 shares of the company’s stock valued at $34,000 after buying an additional 300 shares during the last quarter. Truvestments Capital LLC acquired a new position in AstraZeneca in the 1st quarter valued at $46,000. Finally, Capital Analysts LLC grew its stake in AstraZeneca by 183.9% in the 2nd quarter. Capital Analysts LLC now owns 849 shares of the company’s stock valued at $51,000 after buying an additional 550 shares during the last quarter. Institutional investors own 13.88% of the company’s stock.
A number of research firms recently issued reports on AZN. SVB Leerink raised their target price on shares of AstraZeneca from $71.00 to $73.00 and gave the company an “outperform” rating in a research note on Monday, September 27th. Morgan Stanley reissued an “overweight” rating on shares of AstraZeneca in a report on Friday, September 17th. JPMorgan Chase & Co. started coverage on shares of AstraZeneca in a report on Thursday, August 12th. They issued an “overweight” rating for the company. Citigroup reissued a “buy” rating on shares of AstraZeneca in a report on Wednesday, July 21st. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of AstraZeneca in a report on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average target price of $124.00.
AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Wednesday, July 28th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $8.22 billion during the quarter, compared to the consensus estimate of $7.79 billion. AstraZeneca had a net margin of 12.77% and a return on equity of 40.02%. Sell-side analysts forecast that AstraZeneca PLC will post 2.64 EPS for the current year.
The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 13th. Stockholders of record on Friday, August 13th were issued a dividend of $0.45 per share. This represents a dividend yield of 2.4%. The ex-dividend date was Thursday, August 12th. AstraZeneca’s payout ratio is 68.16%.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Further Reading: Backdoor Roth IRA Conversion and Strategy
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.